BIOCRYST PHARMACEUTICALS INC

BIOCRYST PHARMACEUTICALS INC

Previous company name

Name change date

Company Overview
BioCryst Pharmaceuticals Inc is a publicly quoted company engaged in the design, optimization, and development of novel drugs that block key enzymes involved in cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company has its registered office located in Birmingham, Alabama. It was co-founded by Charles E. Bugg and William M. Spencer III in 1986. The company is publicly traded on the NASDAQ National Market under the trading symbol BCRX.
BioCryst Pharmaceuticals integrates the disciplines of biology, crystallography, medicinal chemistry, and computer modeling to use structure-based drug design to discover and develop small molecule pharmaceuticals. Its lead product candidate, Fodosine, is a transition-state analog inhibitor of the target enzyme purine nucleoside phosphorylase (PNP). This product is in Phase IIa trial for patients with T-cell leukemia and a combination IV, and a Phase I pharmacokinetic trial in healthy volunteers. Additionally, Fodosine is in a Phase I trial with an oral formulation in cutaneous T-cell lymphoma, a Phase II trial in chronic lymphocytic leukemia, and a Phase I/II trial in B-cell acute lymphoblastic leukemia. The company’s pipeline products include PNP Inhibitor (BCX-4208), Hepatitis C Polymerase Inhibitors, Neuraminidase Inhibitor (peramivir), and Tissue Factor/Factor VIIa Inhibitors. PNP Inhibitor (BCX-4208), completed a Phase I single dose pharmacokinetic trial, and is intended for the treatment of T-cell mediated autoimmune diseases, including psoriasis. Hepatitis C Polymerase Inhibitor, a product under preclinical stage, is intended for the treatment of viral infections. Peramivir, a product under preclinical stage, is intended for the treatment of strains of influenza, including the avian strain H5N1. Tissue Factor/Factor VIIa, a product under lead optimization stage, is intended for the treatment of acute coronary syndromes and complications associated with cardiovascular procedures.
BioCryst Pharmaceuticals aims to license or design compounds that will fit in the active sites of enzymes and thereby interfere with the progression of disease. Its strategic alliances are Roche, Mundipharma, Green Cross, and Shionogi & Co. LTD.
Business Summary
BioCryst Pharmaceuticals, Inc. (BioCryst) is a biotechnology company that designs, optimizes and develops novel drugs that block enzymes involved in cancer, viral infections and autoimmune diseases. BioCryst integrates the disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through the process known as structure-based drug design. The Company’s product candidate, forodesine HCl, is a transition-state analog inhibitor of the target enzyme purine nucleoside phosphorylase (PNP). An oral formulation of the compound is in a Phase IIb trial for patients with Cutaneous T-cell Lymphoma (CTCL). Additionally, forodesine HCl is being studied in a Phase II trial with an oral formulation in Chronic Lymphocytic Leukemia (CLL). Its another drug candidate, peramivir, is an inhibitor of influenza neuraminidase.
Description and history
BioCryst Pharmaceuticals, Inc. (BioCryst) is a biotechnology company that designs, optimizes and develops novel drugs that block enzymes involved in cancer, viral infections and autoimmune diseases. BioCryst integrates the disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through the process known as structure-based drug design. The Company’s product candidate, forodesine HCl, is a transition-state analog inhibitor of the target enzyme purine nucleoside phosphorylase (PNP). An oral formulation of the compound is in a Phase IIb trial for patients with Cutaneous T-cell Lymphoma (CTCL). Additionally, forodesine HCl is being studied in a Phase II trial with an oral formulation in Chronic Lymphocytic Leukemia (CLL). Its another drug candidate, peramivir, is an inhibitor of influenza neuraminidase. Peramivir is in development for the treatment of influenza with two parenteral formulations, intramuscular (i.m.) and intravenous (i.v.). Its second generation PNP inhibitor, BCX-4, is in clinical trials.

PNP Inhibitors

PNP is an enzyme that plays a role in T-cell proliferation, because it is necessary to maintain normal DNA synthesis in human T-cells. Forodesine HCl is an investigational PNP inhibitor for the potential treatment of T-cell leukemias and lymphomas. The Company completed a Phase I/II clinical trial of forodesine HCl to determine the safety of repeat doses of an i.v. formulation of the drug in patients with B-ALL. BCX-4208 is a PNP inhibitor as a drug candidate for the treatment of T-cell mediated autoimmune diseases, including psoriasis, and transplant rejection. BCX-4208 has the ability to suppress PNP for longer periods of time.

Neuraminidase Inhibitor

Neuraminidase assists in the release and spread of the flu virus by breaking the chemical strands that hold the new viruses to the cell surface, allowing the replicated virus to spread and infect other cells. This process progresses until the host’s immune response can produce enough antibodies to bring the infection under control. Inhibiting the neuraminidase enzyme keeps new viruses attached to the cell surface, thereby preventing the spread of the virus and the further infection of other cells.

The Company competes with Eisai, GSK and Roche.

Co-founded by Charles E. Bugg and William M. Spencer III

Business Line
Engaged in the design, optimization, and development of novel drugs that block key enzymes involved in cancer, cardiovascular diseases, autoimmune diseases, and viral infections
Subsidiary
BIOCRYST UK LIMITED
Advisor
ERNST & YOUNG LLP
IPO date
3/1994
US SIC Code
2836
Company Address
2190, Parkway Lake Drive

City province or state postal code
35244, BIRMINGHAM, AL
Phone: +1 205 444 4600
Fax: +1 205 444 4640
Country address: UNITED STATES OF AMERICA
Website url: www.biocryst.com